Clin2
NCT06770088Possibly a fitNot yet recruiting

Vunakizumab for adults with spondyloarthritis

Spondyloarthritis (SpA)

Part of Bones, joints & muscles clinical trials.

This trial tests a new biologic drug called Vunakizumab for adults with spondyloarthritis (a type of arthritis affecting the spine). It aims to see if the drug can help control symptoms and inflammation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
880 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with spondyloarthritis (not psoriatic arthritis).
  • You are willing to use effective birth control if you are of childbearing age, for the study period and 20 weeks after.
  • You do not have a serious active infection, moderate to severe heart failure, or an active cancer.
  • You do not have other inflammatory diseases like inflammatory bowel disease that could interfere with the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06881290Recruiting· Phase 1
Vunakizumab for mild to moderate lupus

This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.

Beijing, Beijing Municipality
NCT06766552Not yet recruiting
A study on vunakizumab for rheumatic diseases

This study looks at how well vunakizumab works for people with certain inflammatory rheumatic conditions, like ankylosing spondylitis or psoriatic arthritis. It tracks symptoms, how the medicine is used, and any side effects over time.

Hangzhou
NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis

This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.

Shenyang, Liaoning
NCT06794671Not yet recruiting
Testing vunakizumab for inflammatory skin conditions

This trial is testing the drug vunakizumab in people with inflammatory skin diseases. It aims to see how well the treatment works for different skin conditions.

NCT06779097Not yet recruiting· Phase 4
Testing a new biologic for moderate to severe plaque psoriasis

This study tests a biologic called vunakizumab for people with moderate to severe plaque psoriasis who are already on biologic therapy and need to switch to another one. The goal is to see if it works well and is safe.

Beijing, Beijing Municipality
NCT06526377Not yet recruiting· Phase 2
Vilamakitug for active axial spondyloarthritis

This study tests a new medication called vilamakitug for people with active axial spondyloarthritis. It aims to see if the drug can reduce pain and inflammation better than a placebo (a dummy treatment).

Hear when a new Spondyloarthritis (SpA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.